UniPharma Co., Ltd. (TPEX:6621)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
11.75
+0.55 (4.91%)
Jun 12, 2026, 1:34 PM CST
Market Cap397.61M -22.5%
Revenue (ttm)88.44M -5.4%
Net Income-40.54M
EPS-1.14
Shares Out 35.50M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume73,918
Open11.30
Previous Close11.20
Day's Range11.25 - 11.75
52-Week Range11.20 - 16.00
Beta-0.21
Analystsn/a
Price Targetn/a
Earnings DateAug 7, 2026

About UniPharma

UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan. It provides diagnostic tests in areas of oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. The company offers Adept reduction solution; bain, esmolol HCI, and naloxone anesthesia injections; Elisa DR-70 test for in-vitro diagnostics of tumors; and fomeject antidote injection, as well as drug development, research and development, clinical trials, marketing, and other business services. It serves m... [Read more]

Sector Healthcare
Founded 1998
Employees 34
Stock Exchange Taipei Exchange
Ticker Symbol 6621
Full Company Profile

Financial Performance

In 2025, UniPharma's revenue was 88.44 million, a decrease of -5.36% compared to the previous year's 93.46 million. Losses were -40.54 million, 63.4% more than in 2024.

Financial Statements